{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:06:54Z","timestamp":1785413214213,"version":"3.56.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jbo.2026.100784","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:13:45Z","timestamp":1783379625000},"page":"100784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical application of urinary NTx in patients with bone metastases from lung cancer"],"prefix":"10.1016","volume":"59","author":[{"given":"Lan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejiao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyao","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2026.100784_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1188357","article-title":"Potential biomarkers for the early detection of bone metastases","volume":"13","author":"Hao","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jbo.2026.100784_bb0010","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1089\/thy.2000.10.261","article-title":"Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients","volume":"10","author":"Pittas","year":"2000","journal-title":"Thyroid"},{"key":"10.1016\/j.jbo.2026.100784_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2020.100282","article-title":"Bone metastases in thyroid cancer","volume":"21","author":"I\u00f1iguez-Ariza","year":"2020","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.jbo.2026.100784_bb0020","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/cancers16020252","article-title":"Circulating tumour cells in the prediction of bone metastasis","volume":"16","author":"Choi","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jbo.2026.100784_bb0025","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1158\/0008-5472.CAN-19-0458","article-title":"Defining the hallmarks of metastasis","volume":"79","author":"Welch","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbo.2026.100784_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2009.11.003","article-title":"Mechanisms of breast cancer bone metastasis","volume":"292","author":"Zhang","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jbo.2026.100784_bb0035","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3390\/cancers10060156","article-title":"Multidisciplinary approach for bone metastasis: a review","volume":"10","author":"Kimura","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jbo.2026.100784_bb0040","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.3390\/ijms20102587","article-title":"Prostate Cancer and bone metastases: the underlying mechanisms","volume":"20","author":"Wong","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbo.2026.100784_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016022","article-title":"Survival after bone metastasis by primary cancer type: a Danish population-based cohort study","volume":"7","author":"Svensson","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.jbo.2026.100784_bb0050","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3389\/fonc.2020.00335","article-title":"The Endosteal niche in breast Cancer bone metastasis","volume":"10","author":"Haider","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jbo.2026.100784_bb0055","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/jcb.21214","article-title":"The role of tumor microenvironment in prostate cancer bone metastasis","volume":"101","author":"Morrissey","year":"2007","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.jbo.2026.100784_bb0060","first-page":"379","article-title":"The skeletal metastatic complications of renal cell carcinoma","volume":"19","author":"Zekri","year":"2001","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jbo.2026.100784_bb0065","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jbo.2026.100784_bb0070","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2026.100784_bb0075","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.canep.2019.05.013","article-title":"Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone metastasis or multiple myeloma: a 12-year longitudinal nationwide healthcare database study","volume":"61","author":"Baek","year":"2019","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.jbo.2026.100784_bb0080","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1007\/s00259-025-07085-6","article-title":"[18F]PSMA-1007 PET\/CT-based radiomics may help enhance the interpretation of bone focal uptakes in hormone-sensitive prostate cancer patients","volume":"52","author":"Bauckneht","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jbo.2026.100784_bb0085","article-title":"Elevated N-telopeptide as a potential diagnostic marker for bone metastasis in lung cancer: a meta-analysis","volume":"12","author":"Liu","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jbo.2026.100784_bb0090","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s10585-025-10376-9","article-title":"Borderline decisions in brain-metastatic breast cancer: efficacy of multimodality treatments in breast cancer patients with very limited prognosis suffering from brain metastases","volume":"42","author":"Bendrich","year":"2025","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.jbo.2026.100784_bb0095","doi-asserted-by":"crossref","first-page":"R102","DOI":"10.1186\/ar2494","article-title":"Biochemical markers of bone turnover and their association with bone marrow lesions","volume":"10","author":"Hunter","year":"2008","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jbo.2026.100784_bb0100","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s12094-016-1590-1","article-title":"SEOM clinical guideline for bone metastases from solid tumours (2016)","volume":"18","author":"Gr\u00e1valos","year":"2016","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.jbo.2026.100784_bb0105","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/1759-7714.14808","article-title":"Serum cross-linked N-telopeptide of type I collagen as a potential diagnostic marker for bone metastasis in lung cancer: an updated meta-analysis","volume":"14","author":"Wang","year":"2023","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.jbo.2026.100784_bb0110","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00198-009-0974-2","article-title":"Laboratory reproducibility of biochemical markers of bone turnover in clinical practice","volume":"21","author":"Schafer","year":"2010","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jbo.2026.100784_bb0115","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s13046-022-02520-0","article-title":"Osteoblasts and osteoclasts: an important switch of tumour cell dormancy during bone metastasis","volume":"41","author":"Dai","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2026.100784_bb0120","first-page":"792","article-title":"Navigating the biophysical landscape: how physical cues steer the journey of bone metastatic tumor cells, trends","volume":"10","author":"Ouyang","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2026.100784_bb0125","first-page":"e23505","article-title":"Application of N-terminal telopeptide of type I collagen in the evaluation of bone metastasis degree and efficacy","volume":"43","author":"Zhao","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2026.100784_bb0130","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2002.20.3.850","article-title":"Prospective evaluation of the peptide-bound collagen type I cross-links N-Telopeptide and C-Telopeptide in predicting bone metastases status","volume":"20","author":"Costa","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2026.100784_bb0135","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jbo.2013.01.002","article-title":"Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features\u2014an exploratory analysis of placebo-controlled trials","volume":"2","author":"Coleman","year":"2013","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.jbo.2026.100784_bb0140","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/pros.20917","article-title":"Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid","volume":"69","author":"Lein","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.jbo.2026.100784_bb0145","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/jamaoncol.2023.6520","article-title":"Efficacy, safety, and population pharmacokinetics of MW032 compared with Denosumab for solid tumor-related bone metastases: a randomized, double-blind, phase 3 equivalence trial","volume":"10","author":"Zhang","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jbo.2026.100784_bb0150","doi-asserted-by":"crossref","first-page":"337","DOI":"10.21147\/j.issn.1000-9604.2025.03.04","article-title":"Comparison of efficacy and safety of a proposed biosimilar QL1206 with reference denosumab in patients with bone metastasis from breast cancer: a subgroup analysis of a randomized, double-blinded phase III study","volume":"37","author":"Liu","year":"2025","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.jbo.2026.100784_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2025.100661","article-title":"A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva\u00ae) in patients with bone metastasis from solid tumors","volume":"51","author":"Zhao","year":"2025","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.jbo.2026.100784_bb0160","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jncc.2023.08.004","article-title":"Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)","volume":"3","author":"Duan","year":"2023","journal-title":"J. National Cancer Center"},{"key":"10.1016\/j.jbo.2026.100784_bb0165","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.critrevonc.2011.02.005","article-title":"Consensus on the utility of bone markers in the malignant bone disease setting","volume":"80","author":"Coleman","year":"2011","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jbo.2026.100784_bb0170","first-page":"333","article-title":"Diagnostic value of urinary N-telopeptide of type I collagen in prostate cancer: comparison with bone scintigraphy","volume":"36","author":"Fukumitsu","year":"1999","journal-title":"Kaku Igaku"},{"key":"10.1016\/j.jbo.2026.100784_bb0175","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.urology.2003.09.044","article-title":"Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases","volume":"63","author":"Petrioli","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.jbo.2026.100784_bb0180","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1158\/1078-0432.CCR-15-3086","article-title":"Changes in bone turnover marker levels and clinical outcomes in patients with advanced Cancer and bone metastases treated with bone Antiresorptive agents","volume":"22","author":"Lipton","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2026.100784_bb0185","article-title":"N-telopeptide as a potential diagnostic and prognostic marker for bone metastasis in human cancers: a meta-analysis","volume":"9","author":"Li","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.jbo.2026.100784_bb0190","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/archinte.1997.00440320149014","article-title":"Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density","volume":"157","author":"Schneider","year":"1997","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jbo.2026.100784_bb0195","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in Cancer patients with bone metastases receiving the bisphosphonate Zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2026.100784_bb0200","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.clon.2012.11.004","article-title":"Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses","volume":"25","author":"Lipton","year":"2013","journal-title":"Clin. Oncol. (R Coll Radiol)"},{"key":"10.1016\/j.jbo.2026.100784_bb0205","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2026.100784_bb0210","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3349\/ymj.2005.46.3.388","article-title":"Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung Cancer","volume":"46","author":"Chung","year":"2005","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.jbo.2026.100784_bb0215","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1053\/meta.2002.33344","article-title":"Correlation of urine type I collagen-cross-linked N telopeptide levels with bone scintigraphic results in prostate cancer patients","volume":"51","author":"Fukumitsu","year":"2002","journal-title":"Metabolism"},{"key":"10.1016\/j.jbo.2026.100784_bb0220","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1507\/endocrj.44.751","article-title":"Diagnostic validity of bone metabolic markers for bone metastasis","volume":"44","author":"Miura","year":"1997","journal-title":"Endocr. J."},{"key":"10.1016\/j.jbo.2026.100784_bb0225","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.7314\/APJCP.2012.13.9.4331","article-title":"Markers of bone metastases in breast and lung cancers","volume":"13","author":"Bilgin","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.jbo.2026.100784_bb0230","doi-asserted-by":"crossref","first-page":"e18044","DOI":"10.1200\/jco.2011.29.15_suppl.e18044","article-title":"Diagnosis of bone metastasis in patients with lung cancer using urinary and serum collagen type I telopeptide (NTx)","volume":"29","author":"Okada","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2026.100784_bb0235","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/jbmr.4041","article-title":"Circulating osteocalcin-positive cells as a novel diagnostic biomarker for bone metastasis in breast Cancer patients","volume":"35","author":"Lee","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jbo.2026.100784_bb0240","article-title":"Bone cancer, version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Biermann","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.jbo.2026.100784_bb0245","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2026.100784_bb0250","doi-asserted-by":"crossref","first-page":"20220923","DOI":"10.1515\/biol-2022-0923","article-title":"Predictive value of serum magnesium levels for prognosis in patients with non-small cell lung cancer undergoing EGFR-TKI therapy","volume":"19","author":"Xu","year":"2024","journal-title":"Open Life Sci"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137426000461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137426000461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:30:44Z","timestamp":1785411044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137426000461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":50,"alternative-id":["S2212137426000461"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2026.100784","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical application of urinary NTx in patients with bone metastases from lung cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2026.100784","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100784"}}